Business
RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th
MOUNTAIN VIEW, Calif., April 04, 2025--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced that Chief Executive Officer Shaun Bagai will present at the LD Micro Invitational XV: New York 2025 conference taking place at the Westin Grand Central Hotel, New York, NY on April 10, 2025.
About this update from Renovorx, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/f998aee7a5cfb86ca0a1f3ce4005f5e2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.NEtPG4D0O2k0HhEsQEZCw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/f998aee7a5cfb86ca0a1f3ce4005f5e2","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/hxX0zMr1c0kAA3puX1vXYQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/f998aee7a5cfb86ca0a1f3ce4005f5e2","width":1024,"height":512}},"lazy":false},{"type":"text","content":"CEO Shaun Bagai to discuss the momentum of RenovoRx’s commercialization efforts for its RenovoCath® device, including an update on initial revenues generated, and continued progress on the ongoing Phase III TIGeR-PaC clinical trial","length":231,"tagName":"p","attribs":{}},{"type":"text","content":"MOUNTAIN VIEW, Calif., April 04, 2025--(BUSINESS WIRE)--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced that Chief Executive Officer Shaun Bagai will present at the LD Micro Invitational XV: New York 2025 conference taking place at the Westin Grand Central Hotel, New York, NY on April 10, 2025.","length":493,"tagName":"p"},{"type":"text","content":"Mr. Bagai will discuss recent corporate milestones, including an update on RenovoRx’s continued momentum of its RenovoCath commercial efforts, including new purchase orders and reorders received from cancer center customers, and the realization of initial revenues from RenovoCath sales.","length":287,"tagName":"p"},{"type":"text","content":"Mr. Bagai will also discuss progress on RenovoRx’s ongoing Phase III TIGeR-PaC clinical trial. TIGeR-PaC is evaluating RenovoRx’s lead drug-device combination product candidate (intra-arterial delivery of gemcitabine via the RenovoCath catheter, known as IAG) which uses the proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform for the treatment of locally advanced pancreatic cancer (LAPC). This combination product ca...